Hematopoietic, CNS and skeletal muscle stem cells as drug targets: Opportunities, progress and challenges

Future Medicinal Chemistry

Volumn 4, Issue 5, 2012, Pages 615-623

  Billin, Andrew ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16,16 DIMETHYL PROSTAGLADIN E2; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ELTROMBOPAG; FT 1050; GRANULOCYTE COLONY STIMULATING FACTOR; GW 786460X; LINAGLIPTIN; MOBIZIL; PLERIXAFOR; PROSTAGLANDIN E2; PROTEIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ADULT STEM CELL; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CENTRAL NERVOUS SYSTEM STEM CELL; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG STRUCTURE; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; MULTIPLE MYELOMA; NERVOUS SYSTEM DEVELOPMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE STEM CELL;

ANTIGENS, CD34; HEMATOPOIETIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIGANDS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STEM CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84859455037     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.5     Document Type: Review

References (49)

1. Blair K, Wray J, Smith A. The liberation of embryonic stem cells. PLoS Genet. 7(4), e1002019 (2011).
2. Yu J, Thomson JA. Pluripotent stem cell lines. Genes Dev. 22(15), 1987-1997 (2008).
3. Bretzner F, Gilbert F, Baylis F, Brownstone RM. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8(5), 468-475 (2011).
4. Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nature Biotechnol. 28(10), 989-990 (2010).
5. Smith JA, Glantz M. Statistical and trial design considerations in central nervous system prophylaxis studies. Semin. Oncol. 36(4 Suppl. 2), S69-S76 (2009).
6. Alper J. Geron gets green light for human trial of ES cell-derived product. Nature Biotechnol. 27(3), 213-214 (2009).
7. Puceat M, Ballis A. Embryonic stem cells: From bench to bedside. Clin. Pharmacol. Ther. 82(3), 337-339 (2007). (Pubitemid 47258473)
8. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006). (Pubitemid 44233629)
9. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336), 63-67.
10. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471(7336), 58-62 (2011).
11. Lister R, Pelizzola M, Kida YS et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471(7336), 68-73 (2011).
12. Lombardero M, Kovacs K, Scheithauer BW. Erythropoietin: A hormone with multiple functions. Pathobiology 78(1), 41-53 (2011).
13. Wiedmann MW, Mossner J, Baerwald C, Pierer M. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr. Metab. Immune Disord. Drug Targets 9(3), 295-314 (2009).
14. Bhana N. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: Evidence based review. Curr. Opin. Oncol. 19(4), 328-335 (2007). (Pubitemid 46883521)
15. Cheng G. Eltrombopag for the treatment of immune thrombocytopenia. Expert Rev. Hematol. 4(3), 261-269 (2011).
16. Garnock-Jones KP. Eltrombopag: A review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs 71(10), 1333-1353 (2011).
17. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst. Rev. 7, CD008235 (2011).
18. Erickson-Miller CL, Delorme E, Tian SS et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27(2), 424-430 (2009).
19. Mohty M, Duarte RF, Croockewit S, Hubel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25(1), 1-6 (2011).
20. Kessans MR, Gatesman ML, Kockler DR. Plerixafor: A peripheral blood stem cell mobilizer. Pharmacotherapy. 30(5), 485-492 (2010).
21. Brave M, Farrell A, Ching Lin S et al. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78(3-4), 282-288 (2010).
22. Grignani G, Perissinotto E, Cavalloni G, Carnevale Schianca F, Aglietta M. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. J. Clin. Oncol. 23(16), 3871-3873 (2005).
23. Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl Acad. Sci. USA 86(10), 3828-3832 (1989). (Pubitemid 19141838)
24. Rocha V, Broxmeyer HE. New approaches for improving engraftment after cord blood transplantation. J. Blood Marrow Trans. 16(Suppl.1), S126-S132 (2010).
25. Broxmeyer HE, Cooper S, Hass DM, Hathaway JK, Stehman FB, Hangoc G. Experimental basis of cord blood transplantation. J. Bone Marrow Trans. 44(10), 627-633 (2009).
26. Goessling W, Allen RS, Guan X et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-Term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8(4), 445-458 (2011).
27. North TE, Goessling W, Walkley CR et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447(7147), 1007-1011 (2007). (Pubitemid 46975751)
28. Boitano AE, Wang J, Romeo R et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329(5997), 1345-1348 (2010).
29. Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: A novel approach to enhance transplantation. Front. Biosci. 13, 1795-1805 (2008). (Pubitemid 351599733)
30. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev. 16(3), 347-354 (2007).
31. Flatt PR, Bailey CJ, Green BD. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr. Drug Metab. 10(2), 125-137 (2009).
32. Curtis MA, Kam M, Faull RL. Neurogenesis in humans. Eur. J. Neurosci. 33(6), 1170-1174 (2011).
33. Ming GL, Song H. Adult neurogenesis in the mammalian brain: Significant answers and significant questions. Neuron 70(4), 687-702 (2011).
34. Pieper AA, Wu X, Han TW et al. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. Proc. Natl Acad. Sci. USA 102(39), 14052-14057 (2005). (Pubitemid 41377701)
35. Pieper AA, Xie S, Capota E et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 142(1), 39-51 (2010).
36. Macmillan KS, Naidoo J, Liang J et al. Development of proneurogenic, neuroprotective small molecules. J. Am. Chem. Soc. 133(5), 1428-1437 (2011).
37. Collins CA, Partridge TA. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle 4(10), 1338-1341 (2005). (Pubitemid 41437116)
38. Partridge T. Re-enthronement of the muscle satellite cell. Cell 119(4), 447-448 (2004).
39. Ciciliot S, Schiaffino S. Regeneration of mammalian skeletal muscle. Basic mechanisms and clinical implications. Curr. Pharm. Des. 16(8), 906-914 (2010).
40. Jones DL, Rando TA. Emerging models and paradigms for stem cell ageing. Nat. Cell Biol. 13(5), 506-512 (2011).
41. Liu L, Rando TA. Manifestations and mechanisms of stem cell aging. J. Cell Biol. 193(2), 257-266 (2011).
42. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 454(7203), 528-532 (2008).
43. Carlson ME, Conboy MJ, Hsu M et al. Relative roles of TGF-beta1 and Wnt in the systemic regulation and aging of satellite cell responses. Aging Cell 8(6), 676-689 (2009).
44. Anderton MJ, Mellor HR, Bell A et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39(6) 916-924 (2011).
45. Solanki A, Lee KB. A step closer to complete chemical reprogramming for generating iPS cells. Chembiochem 11(6), 755-757 (2010).
46. Ichida JK, Blanchard J, Lam K et al. A small-molecule inhibitor of tgf-beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 5(5), 491-503 (2009).
47. Maherali N, Hochedlinger K. TgfBeta signal inhibition cooperates in the induction of iPSCs and replaces sox2 and cMyc. Curr. Biol. 19(20), 1718-1723 (2009).
48. Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 4(4), 301-312 (2009).
49. Ong SE, Schenone M, Margolin AA et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl Acad. Sci. USA 106(12), 4617-4622 (2009).